- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04046081
A Clinical Trial to Evaluate Dichloroacetate (DCA) as a Treatment for Endometriosis-associated Pain (EPiC)
December 2, 2019 updated by: University of Edinburgh
A Single-arm Open Label Exploratory Clinical Trial to Evaluate Dichloroacetate (DCA) as a Possible Treatment for Endometriosis-associated Pain
This is a single-arm open label exploratory clinical trial to evaluate dichloroacetate (DCA) as a possible treatment for treatment of endometriosis-associated pain
Study Overview
Detailed Description
Endometriosis is a chronic condition usually affecting women throughout their reproductive lives.
It is defined as a growth of endometrial-like tissue (womb lining) outside the uterus (womb) and is associated with chronic pelvic pain that can be frequent and severe, resulting in tiredness, lower quality of life and difficulties in getting pregnant.
Current treatments are unsatisfactory and there is an unmet need for new medical treatment for endometriosis.
Research findings from our laboratory have shown that women with endometriosis have more lactate in their pelvis.
In laboratory models of endometriosis, we have tested dichloroacetate (DCA), a compound used to treat metabolic disorders in children.
Our results showed that DCA could stop the growth and survival of endometriosis cells and reduce lactate production.
In our study we plan to investigate if we can we can recruit and retain women into a trial using this treatment.
We will recruit 30 women aged 18 or over, with pelvic pain and a diagnosis of endometriosis within the last three years.
Participants will complete informed consent, be willing to comply with the treatment and use contraception throughout the trial.
We will recruit patients over six months at Royal Infirmary of Edinburgh.
Women who consent will take a daily dose of DCA capsules for 12 weeks.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Edinburgh, United Kingdom
- Recruiting
- Royal Infirmary of Edinburgh
-
Contact:
- Priscilla Fernandez
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women aged 18 or over
- Weight between 50 and 100kg
- Pre-menopausal
- Superficial peritoneal endometriosis (ASRM Stage I or II) at laparoscopy, performed within the last three years (and >2 weeks from surgery)
- Pelvic pain for longer than six months
- Average pain score of ≥ 4 over the four weeks prior to treatment
- Willing to comply with the treatment
- Willing to use contraception throughout the trial
- Willing and able to complete informed consent
Exclusion Criteria:
- Evidence of ovarian endometrioma or deep endometriosis (based upon current surgical staging or most recent imaging)
- Women who are pregnant or actively trying to get pregnant
- Known allergy or hypersensitivity to any excipient of DCA
- Breastfeeding
- Clinical evidence of pre-existing neuropathy
- Diabetes
- History of liver disease
- History of kidney disease
- Taking part in a CTIMP or other interventional non-CTIMP studies
- Patient on combination antiretroviral therapy
- History of malabsorption syndrome or substantial amount of small bowels or stomach removed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Dichloroacetate
Open label study
|
6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine whether it is possible to achieve acceptable recruitment and retention rates within defined inclusion/exclusion criteria.
Time Frame: Screening
|
The proportion of screened women who are eligible for the trial determined from the screening logs
|
Screening
|
To determine whether it is possible to achieve acceptable recruitment and retention rates within defined inclusion/exclusion criteria.
Time Frame: Screening
|
The proportion of eligible patients recruited to the study recorded on the screening logs
|
Screening
|
To determine whether it is possible to achieve acceptable recruitment and retention rates within defined inclusion/exclusion criteria.
Time Frame: Throughout the treatment (Week 1- 12)
|
The proportion of recruited patients who answer their average NRS scores at visits 3 and 5, complete the assessment tools (questionnaires) and attend for designated blood testing
|
Throughout the treatment (Week 1- 12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the acceptability to patients of the proposed methods of recruitment, treatment, questionnaires and follow up.
Time Frame: Week 16
|
Assessed by acceptability questionnaire at the end of study asking questions about participants' satisfaction with the methods of recruitment, treatment, questionnaires and follow up
|
Week 16
|
To assess whether dichloroacetate is well-tolerated in women with endometriosis.
Time Frame: Throughout the treatment up to week 16
|
Self-reported side effects during and after the treatment
|
Throughout the treatment up to week 16
|
To determine participants' compliance with treatment and to assess the tools used to measure it.
Time Frame: Throughout the treatment (Week 1- 12)
|
Assessed by self-report using treatment diaries to measure number of doses taken
|
Throughout the treatment (Week 1- 12)
|
To determine participants' compliance with treatment and to assess the tools used to measure it.
Time Frame: Throughout the treatment (Week 1- 12)
|
Assessed by measuring levels of systemic dichloroacetate from blood samples using mass spectrometry
|
Throughout the treatment (Week 1- 12)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2019
Primary Completion (Anticipated)
May 19, 2020
Study Completion (Anticipated)
August 31, 2020
Study Registration Dates
First Submitted
July 31, 2019
First Submitted That Met QC Criteria
August 2, 2019
First Posted (Actual)
August 6, 2019
Study Record Updates
Last Update Posted (Actual)
December 4, 2019
Last Update Submitted That Met QC Criteria
December 2, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC18127
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Selected anonymised data collected or generated by the study will be shared with commercial collaborators once the study is finished.
IPD Sharing Time Frame
Completion of the trial, published online, available indefinitely.
IPD Sharing Access Criteria
Anonymized results will be shared with other researchers.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometriosis
-
Fabio BarraCompletedEndometriosis | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis Pelvic | Endometriosis of ColonItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis | Bowel Endometriosis | Endometriosis, Rectum | Endometriosis ColonItaly
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedEndometriosis | Endometriosis-related Pain | Endometriosis Thoracic | Endometriosis of Lung | Endometriosis of PleuraItaly
-
BioGene Pharmaceutical Ltd.WithdrawnSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis ExternaSwitzerland
-
Ospedale Policlinico San MartinoCompletedEndometriosis, Rectum | Endometriosis, SigmoidItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownBowel Endometriosis | Endometriosis, RectumItaly
-
Ospedale Policlinico San MartinoActive, not recruitingEndometriosis, Rectum | Endometriosis of ColonItaly
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
-
Universitaire Ziekenhuizen KU LeuvenUniversity of Sydney; University of CagliariActive, not recruitingEndometriosis | Surgery | Gynecologic Disease | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis of Colon | Endometriosis of BladderBelgium, Italy, Australia
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingEndometriosis | Endometriosis-related Pain | Endometriosis of Umbilicus | Endometriosis in Scar of SkinItaly
Clinical Trials on Dichloroacetate
-
AHS Cancer Control AlbertaCross Cancer InstituteCompleted
-
National Institute of Environmental Health Sciences...Completed
-
Sanford HealthCompletedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Yale UniversityNot yet recruitingDiabetes Mellitus, Type 1 | Hypoglycemia Unawareness
-
University of California, San DiegoCompletedLactic AcidosisUnited States
-
University of AlbertaCapital Health, CanadaCompletedMalignant Gliomas, Glioblastoma MultiformeCanada
-
Eunice Kennedy Shriver National Institute of Child...Unknown
-
Jonsson Comprehensive Cancer CenterTerminatedLung Cancer | Metastatic Breast CancerUnited States
-
University of FloridaCompleted
-
University of FloridaNo longer availableMitochondrial Enzyme DeficienciesUnited States